SEHK:2186Pharmaceuticals
A Look At Luye Pharma Group (SEHK:2186) Valuation After Ruoxinlin NDA Acceptance For Anxiety Disorder
Luye Pharma Group (SEHK:2186) is in focus after Chinese regulators accepted a New Drug Application for a new Ruoxinlin indication targeting Generalized Anxiety Disorder, supported by Phase III data in a large patient population.
See our latest analysis for Luye Pharma Group.
The NDA news has arrived after a mixed period for Luye Pharma Group. The 30 day share price return is 5.99%, while the 90 day share price return shows a 16.16% decline. The 1 year total shareholder return of 49.75%...